Treatment of genetic diseases by gene therapy is hampered by immune responses against the transgene product. The risk of a humoral immune response against the transgene product in experimental gene transfer studies is influenced by multiple factors, including the type and design of gene transfer vectors, vector dose, transgene expression levels, route of administration, the underlying native gene mutation and the murine strain. [1] [2] [3] [4] [5] The formation of antibodies against the transgene product requires engagement of CD4 + T cells to a specific peptide antigen-major histocompatibility complex (MHC) class II complex on the surface of antigen-presenting cells. A similar interaction between CD4 + T helper cells and B cells can induce B-cell activation and antibody formation. Besides T-cell receptor signaling (signal 1), activation of naive T cells is dependent on co-stimulatory signals from antigen-presenting cells (signal 2). Expression of co-stimulatory molecules on antigen-presenting cells requires activation of these cells by cytokines or pathogen-associated molecular patterns. Insufficient co-stimulation may induce tolerance. 6 Adenoviral vectors engage pattern recognition receptors such as Toll-like receptor (TLR)2 and TLR9 [7] [8] [9] known to initiate pro-inflammatory responses and to induce expression of co-stimulatory molecules.
Immunological unresponsiveness to the transgene product may occur as a consquence of immunological tolerance or immunological ignorance. 10 The distinction between both forms of immunological unresponsiveness can be made by challenging mice with subcutaneous administration of the neo-antigen formulated in complete Freund's adjuvant several weeks after gene transfer. 10, 11 In the case of immunological tolerance, no antibodies appear after classical immunization, whereas in the case of immunological ignorance, classical immunization will break the immunological unresponsiveness. The risk of antibody formation against the transgene product may be limited by hepatocyte-directed gene transfer [11] [12] [13] and even more pronounced by restricting transgene expression to hepatocytes using hepatocyte-specific expression cassettes. 10, 14 Whether use of potent hepatocyte-specific expression cassettes consistently prevents the occurrence of a humoral immune response against the transgene product is currently unclear.
We have previously shown that expression of a transgene product from the Eb promoter, an MHC class II promoter, is associated with a vigorous humoral immune response against human apolipoprotein (apo) A-I in Balb/c mice. 10 This suggests highly efficient class II presentation of peptides derived from endogenously synthesized proteins in antigen-presenting cells. ) mice and outbred Swiss Webster mice. AdA-I is an E1E3E4-deleted vector containing a potent hepatocytespecific expression cassette consisting of the 1.5 kb human a 1 -antitrypsin promoter upstream of the genomic human apo A-I sequence and four copies of the human apo E enhancer. 16 Figure 1a shows that human apo A-I expression persisted for the entire duration of the experiment in all six strains. No antibodies against human apo A-I were observed in any strain. In inbred strains, human apo A-I levels were stable in C57BL/6, 129 and Fvb mice whereas a significant decline at later time points was observed in Balb/c and C3H/HeJ mice. Lower expression levels in these two strains correlated with a decline of transgene DNA levels in the liver between day 35 and 4 months (3.0-fold, Po0.001, in Balb/c mice and 1.9-fold, Po0.05, in C3H/HeJ mice) whereas stable transgene DNA levels were observed in the other strains (Table 1) . We also observed a decline of transgene expression (data not shown) and of transgene DNA levels (Table 1) in the liver of C3H/HeJ beige mice, indicating that it was not caused by natural killer cell activity.
To study whether immunological unresponsiveness after transfer with AdA-I is the result of immunological tolerance and to evaluate whether immunological tolerance is dependent on transgene expression levels, we performed gene transfer with 5 Â 10 10 or 1 Â 10 10 particles of AdA-I in Balb/c mice. Human apo A-I levels after transfer with 1 Â 10 10 particles were below 5 mg per 100 ml ( Figure 1a) . In separate experiments, classical Mice were injected with 50 mg of human apo A-I formulated in complete Freund adjuvant in the footpad of each hindlimb at day 21 (arrow). Rechallenge was performed by injecting 50 mg of human apo A-I formulated in incomplete Freund adjuvant in the footpad of each hindlimb at day 56 (arrow). Human apo A-I antibodies were determined as described previously. 24 Data are expressed as the geometric means ± standard error of the geometric means (n ¼ 5 to 10 for each experimental condition). Quantification of human apo A-I DNA was performed by real-time PCR as described previously. 24 The human apo A-I DNA copy number was normalized to the copy number of the Prion Protein (PrP) gene. Data are expressed as means ± s.e.m. Each experimental condition consisted of 5-10 mice. *Po0.05; ***Po0.001 for difference between day 35 and day 120.
Antigen particles of AdA-I, indicating tolerance for human apo A-I. In contrast, a humoral immune response was observed in mice injected with 1 Â 10 10 particles of AdA-I. However, compared to Balb/c mice immunized with human protein at days 21 and 56 after saline injection, the titers of antibodies were significantly lower in mice injected with 1 Â 10 10 particles of AdA-I (Figure 1b) . Taken together, immunological unresponsiveness for human apo A-I in mice does not necessarily reflect the presence of immunological tolerance.
We have previously shown that a strong humoral immune response against human apo A-I occurs after transfer with an MHC class II-driven vector (AdEb) in Balb/c mice. 10 To evaluate whether endogenous expression of human apo A-I in antigen-presenting cells consistently induces a strong humoral immune response independent of the genetic background, we evaluated the efficacy of AdEb to induce immunoglobulin G (IgG) antibodies against the transgene product in C57BL/6, 129, C3H/HeJ, Fvb and Swiss Webster mice (Figure 2 ). For comparison, antibody titers were also evaluated after gene transfer with AdCMV, containing the ubiquitously active cytomegalovirus (CMV) promoter upstream of the genomic human apo A-I sequence. 17 AdCMV also induces a strong humoral immune response against the transgene product in Balb/c mice. 10, 15 Taken the data in different strains together, AdEb induces a moderate-tostrong humoral immune response in C57BL/6, C3H/HeJ and Swiss Webster mice but no or a very weak immune response in 129 and Fvb mice. In contrast, AdCMV induces a moderate-to-strong immune response in 129 and Fvb mice but no or very low titers of antibodies against human apo A-I in C57BL/6, C3H/HeJ and Swiss Webster mice.
To investigate whether use of potent hepatocytespecific expression cassettes consistently results in the absence of a humoral immune response against the transgene product, we injected 5 Â 10 10 particles of Adplasm or Admplasm in C57BL/6 mice. Adplasm and Admplasm induce expression of human plasminogen (92 kDa) and of human microplasminogen (28.6 kDa), respectively. Expression in these vectors is under control of the 1.5 kb human a 1 -antitrypsin promoter and four copies of the human apo E enhancer, similar as in AdA-I vectors, and occurs exclusively in hepatocytes. Figure 3a shows that plasminogen levels significantly dropped between days 6 and 10 after transfer with Adplasm. This coincided with the appearance of IgG antibodies against human plasminogen (Figure 3c ), indicating that use of a potent hepatocyte-specific expression cassette is not consistently associated with immunological unresponsiveness. In contrast, hepatocyte-specific expression of human microplasminogen in C57BL/6 mice following gene transfer of 5 Â 10 10 particles of Admplasm resulted in stable expression levels for the entire duration of the experiment (Figure 3b) . No antibodies against human microplasminogen were observed (Figure 3c) .
Taken together, these data indicate a lack of predictability of humoral immune responses in the framework of adenoviral gene transfer. As a general rule, immunological unresponsiveness for a transgene product has been more frequently observed in a C57BL/6 background than in a Balb/c background. C57BL/6 mice preferentially develop a predominantly Th1-type immune response whereas Balb/c mice develop a Th2-type immune response. 18 Restricting transgene expression to hepatocytes instead of using ubiquitously active promoters has been shown to be a successful strategy to avoid the development of a humoral immune response in several studies. 10, 11, 14, 15, 19 However, the current study highlights that, even when expression is under control of potent hepatocyte-specific expression cassettes, immunological unresponsiveness and tolerance induction against the transgene product following gene transfer are dependent on the antigen that is expressed. A humoral immune response against human plasminogen after transfer with vectors containing the same expression cassette as used in the AdA-I vector occurred in C57BL/6 mice. Because tolerance for the transgene product in general more easily occurs in the C57BL/6 background than in other backgrounds, this observation seriously undermines the reliability of strategies to abrogate immune responses against the transgene product. Earlier studies have shown that avoiding antibody responses to factor VIII after hepatic factor VIII gene transfer in murine and canine models has been more difficult to obtain than after factor IX gene transfer. 17, 20 Restricting expression to hepatocytes by using a human a 1 -antitrypsin promoter was also insufficient to prevent inhibitor formation against factor VIII.
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Larger antigens, such as human factor VIII or human plasminogen, contain more potentially immunogenic peptides and this number will further increase on knockout backgrounds.
Besides the antigen and the degree of transcriptional targeting, the presence or absence of an immune response may be related to the level and change of antigen exposure. 10, 22 The current study confirms that antigen levels have to be sufficiently high to induce tolerance for human apo A-I.
Another dimension in the lack of predictability of humoral immune responses against the transgene product after gene transfer comes from our previous observations in multiple rabbit strains. 23 Whereas the absence of a humoral immune response against human apo A-I following hepatocyte-directed transfer was observed in six different murine strains in the current study, we have previously observed a vigorous humoral immune response against human apo A-I in three different rabbit strains following transfer with AdA-I. 23 This indicates that the consistent absence of a humoral immune response against a defined transgene product in multiple murine strains may not be predictive of events in higher species.
The immunogenicity of proteins remains poorly understood. Cells and intracellular pathways leading to the formation of peptide-MHC complexes are intricate and variable. 24 The conversion of exogenous and endogenous proteins into immunogenic peptides involves highly variable routes and cell biological events that culminate into the presentation of peptides on MHC class I or class II molecules. Whereas the paradigm that MHC I ligands are derived from endogenous cytosolic proteins and MHC II ligands are from an exogenous source encountering MHC II molecules following endocytosis is still largely correct, these boundaries can clearly be crossed. 24, 25 Thus, endogenous expression of antigens is not only relevant for MHC I presentation but also leads to MHC II presentation. 25 In dendritic cells, MHC II is constitutively synthesized and loaded at endosomes with peptides from either hydrolyzed endogenously expressed proteins or exogenously acquired antigens. Hepatocyte-specific promoters abolish transgene expression in professional antigen-presenting cells such as dendritic cells, whereas an MHC II promoter results in antigen expression selectively in antigenpresenting cells. The effect of transcriptional targeting on MHC I and MHC II presentation will be dependent on cell biological events of antigen processing that are dependent on the antigen and the genetic context. We have previously shown that expression of a transgene product from the Eb promoter, an MHC class II promoter, is associated with a vigorous humoral immune response against human apo A-I in Balb/c mice, suggesting highly efficient class II presentation on antigen-presenting cells of peptides derived from an endogenously synthesized protein. 10 However, in the current study, we show that, whereas the Eb promoter is clearly superior to the CMV promoter to induce antibodies against human apo A-I in C57BL/6, C3H/ HeJ and Swiss Webster mice, the reverse is observed in Fvb and 129 mice. This suggests significant differences in There may also be a lack of predictability of cellular immune responses. Avoiding off-target expression of the transgene in hematopoietic lineage cells by use of microRNA-regulated vectors 26 may abrogate a cellular immune response for certain antigens and in certain genetic backgrounds, whereas in other conditions, efficient cross-presentation may take place.
In conclusion, the current study indicates that the molecular design of strategies to induce either immunological tolerance for the transgene product or a robust adaptive immune response against the transgene product may be hampered significantly by the complexity of cell biological events leading to MHC presentation.
